Related Experiment Video
Updated: Sep 30, 2025

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Effect of Cerebral Microbleeds on Cognitive Function and Quality of Life in Parkinson Disease
Qixiong Qin1, Hengming Wan2, Danlei Wang1
1Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China (mainland).
Abstract:
BACKGROUND This study aimed to investigate the risk factors and patterns of cerebral microbleeds (CMBs) in Parkinson disease (PD) and the impact of CMBs on cognitive function and quality of life (QoL). MATERIAL AND METHODS Patients with PD that underwent susceptibility-weighted imaging were recruited and divided into CMB-free, lobar-CMB, deep-CMB, and mixed-CMB groups according to CMB location. Motor function (MDS-UPDRS III), cognitive abilities (MoCA, MMSE), and QoL (PDQ-39) were compared among groups. The risk factors for CMBs in patients with PD and the association between CMBs and cognition and QoL were analyzed using multivariable logistic regression models and linear regression models. RESULTS Among the 209 patients with PD, 42 (20.1%) had CMBs. Lobar, deep, and mixed CMBs were observed in 15 (35.7%), 17 (40.5%), and 10 (23.8%) patients, respectively. A higher frequency of hypertension was independently associated with deep CMBs (odds ratio [OR]=4.379, 95% CI: 1.405-13.643, P=0.011). The deep-CMB and mixed-CMB groups had lower MoCA scores and MMSE scores than the CMB-free group, especially in domains of naming, attention, and orientation (P<0.05). Additionally, the presence of CMBs was associated with lower MMSE (R²=0.140, ß=-0.301, P<0.001) and MoCA (R²=0.104, ß=-0.289, P<0.001) and higher PDQ-39 (R²=0.052, ß=0.227, P<0.05) scores, while the association between CMBs and PDQ-39 disappeared after adjustment of MMSE or MoCA as a covariate. CONCLUSIONS The results suggest that hypertension was associated with the occurrence of deep CMBs. Comorbidity with CMBs may impair cognitive function and indirectly reduce the QoL in patients with PD.
Insights
Hypertension is linked to deep cerebral microbleeds (CMBs) in Parkinson disease (PD). These CMBs negatively impact cognitive function and indirectly reduce quality of life (QoL) in PD patients.
Area of Science:
- Neurology
- Neuroimaging
- Neurodegeneration
Background:
- Cerebral microbleeds (CMBs) are increasingly recognized in neurodegenerative diseases.
- Understanding CMBs in Parkinson disease (PD) is crucial for managing cognitive decline and quality of life (QoL).
Purpose of the Study:
- To investigate risk factors for CMBs in PD patients.
- To analyze the patterns of CMBs (lobar, deep, mixed) in PD.
- To assess the impact of CMBs on cognitive function and QoL in PD.
Main Methods:
- Susceptibility-weighted imaging was used to detect CMBs in 209 PD patients.
- Patients were categorized into CMB-free, lobar-CMB, deep-CMB, and mixed-CMB groups.
- Motor function, cognition (MoCA, MMSE), and QoL (PDQ-39) were evaluated; regression models analyzed risk factors and associations.
Main Results:
- 20.1% of PD patients had CMBs, with deep CMBs being most frequent (40.5%).
- Hypertension was significantly associated with deep CMBs (OR=4.379, P=0.011).
- Deep and mixed CMB groups showed lower MoCA and MMSE scores, particularly in naming, attention, and orientation. CMBs correlated with poorer cognitive scores and higher PDQ-39 scores, though this QoL association was mediated by cognitive function.
Conclusions:
- Hypertension is an independent risk factor for deep CMBs in PD.
- CMBs are associated with cognitive impairment in PD patients.
- CMBs may indirectly worsen QoL in PD through their effect on cognition.
More Related Videos
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
10:28Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Neural Regulation